Benzinga · Mar 2, 2026
Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop
Alaunos shares fall after ALN1003 shows up to 12.9% weight loss in mice, with liver and metabolic improvements reported.
TC
NASDAQ · TCRT
Alaunos Therapeutics, Inc.
Healthcare · Biotechnology
$0.74
Down-$0.05 (-6.65%)
Updated Oct 7, 2026, 12:20 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 9.6M
- P/E ratio
- -2,332.19
- Dividend yield
- 0.00%
- 52-week range
- $0.78 – $4.59
- Volume
- 121.37K
- Avg. volume
- 439.45K
Price performance · TCRT
TCRT price history
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 6, 2026
TCRT closed at $0.74 after 21 trading sessions, down 52.71% for the selected period.
- Last close
- $0.74
- Period change
- -52.71%
- Period low
- $0.74
- Period high
- $1.60
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 6, 2026 | $0.79 | $0.823 | $0.719 | $0.7425 | 121.37K |
| Oct 5, 2026 | $0.81 | $0.82 | $0.7761 | $0.7953 | 49.4K |
| Oct 2, 2026 | $0.8985 | $0.935 | $0.8165 | $0.82 | 86.83K |
| Oct 1, 2026 | $0.91 | $0.951 | $0.89 | $0.92 | 93.77K |
| Sep 30, 2026 | $0.9521 | $0.9999 | $0.8529 | $0.8875 | 125.84K |
| Sep 29, 2026 | $1.03 | $1.0473 | $0.9601 | $0.9605 | 36.86K |
| Sep 28, 2026 | $1.06 | $1.1044 | $0.9692 | $1.02 | 149.26K |
| Sep 25, 2026 | $1.13 | $1.13 | $1.08 | $1.09 | 82.78K |
| Sep 24, 2026 | $1.14 | $1.16 | $1.10 | $1.13 | 196.93K |
| Sep 23, 2026 | $1.21 | $1.27 | $1.1005 | $1.15 | 207.56K |
| Sep 22, 2026 | $1.19 | $1.34 | $1.17 | $1.27 | 368.48K |
| Sep 21, 2026 | $1.26 | $1.35 | $1.22 | $1.26 | 672.65K |
| Sep 18, 2026 | $1.565 | $1.60 | $1.02 | $1.20 | 32.77M |
| Sep 17, 2026 | $1.35 | $1.65 | $1.2901 | $1.60 | 15.14M |
| Sep 16, 2026 | $1.41 | $1.415 | $1.28 | $1.28 | 37.29K |
| Sep 15, 2026 | $1.4748 | $1.49 | $1.41 | $1.41 | 15.84K |
| Sep 14, 2026 | $1.50 | $1.54 | $1.49 | $1.49 | 9.63K |
| Sep 11, 2026 | $1.52 | $1.53 | $1.495 | $1.51 | 18.28K |
| Sep 10, 2026 | $1.53 | $1.5596 | $1.52 | $1.5596 | 5.28K |
| Sep 9, 2026 | $1.60 | $1.60 | $1.55 | $1.56 | 17.23K |
| Sep 8, 2026 | $1.63 | $1.63 | $1.56 | $1.57 | 15.72K |
Latest TCRT news
The latest Smart Investors Daily articles mentioning TCRT.
Stock researchCompany · Overview
Company
Market Activity
Research & News
TCRT research
Overview
Company profile and research snapshot.
Company profile
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 16, 2023 | HC Wainwright & Co. | Neutral | — |
| Aug 15, 2023 | Laidlaw & Co. | Hold | — |
| May 15, 2023 | HC Wainwright & Co. | Buy | — |
| May 4, 2022 | Wells Fargo | Overweight | — |
News briefing
No generated briefing is available yet.
Benzinga · Mar 2, 2026
Alaunos Therapeutics Announces Early Data From Two Non-GLP DIO Mouse Studies Evaluating ALN1003 For Treating Obesity And Related Conditions
The lead drug candidate, ALN1003, showed dose-related body weight loss and favorable body composition changes in the DIO mouse modelALN1003 also demonstrated reductions in liver weight and improvements in select
Yahoo · Nov 14, 2025
Ziopharm: Q3 Earnings Snapshot
HOUSTON (AP) — Alaunos Therapeutics, Inc. TCRT) on Friday reported a loss of $1.2 million in its third quarter. The Houston-based company said it had a loss of 55 cents per share.
Zacks Investment Research · Aug 31, 2023
J&J (JNJ) Updates 2023 Guidance After Final Kenvue Separation
With the complete separation of the Consumer Health segment, J&J (JNJ) is now a two-sector company focused on the Pharmaceutical and MedTech fields.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
